Becker's Healthcare December 23, 2019
To gain approval for a new drug or a new use of an existing one, drugmakers are shifting away from conducting traditional clinical trials and instead determining the efficiency of a drug by analyzing data sets from electronic medical records, according to The Wall Street Journal.
Clinical trials are often expensive and can take years. By looking at data from electronic medical records, drugmakers can see how a drug performs in a matter of months and avoid costly clinical trials.
Pfizer, Johnson & Johnson and Amgen have used health record analyses when seeking FDA approval for a new drug or for a new use of an existing drug, according to the Journal. The FDA has approved new uses for...
Today's Sponsors
Today's Sponsor